Evidence map›Paper›PMID 22903347›Full record

ReviewCancer immunology, immunotherapy : CII2012

Endothelial cells in the eyes of an immunologist.

M Rita Young

Abstract readReview
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. 3D Printing for Neural Repair: Bridging the Gap in Regenerative Medicine.Advanced materials (Deerfield Beach, Fla.) · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Sourcing cells forFrontiers in medical technology · 2022
    Review
  10. Article
  11. Article
  12. Review
  13. Roles of Immune Cells in Hereditary Angioedema.Clinical reviews in allergy & immunology · 2021
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

M Rita YoungResearch Services, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC 29401, USA. rita.young@va.gov
Ralph H. Johnson VA Medical Center · US

Funding

Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.R01CA128837 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YOUNG, M. RITA · 2009 to 2013
$1.5M
Macrophage-driven progression of premalignant oral lesions toward invasivenessR01DE018168 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YOUNG, M. RITA · 2008 to 2011
$1.2M
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune ReactivityI01CX000100 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI YOUNG, M. RITA · 2009 to 2014
–
CSRD VA I01 CX000100NCI NIH HHS R01 CA128837NIDCR NIH HHS R01 DE018168NIDCR NIH HHS R01 DE018268
6 · The paper itself

Abstract

Endothelial cell activation in the process of tumor angiogenesis and in various aspects of vascular biology has been extensively studied. However, endothelial cells also function in other capacities, including in immune regulation. Compared to the more traditional immune regulatory populations (Th1, Th2, Treg, etc.), endothelial cells have received far less credit as being immune regulators. Their regulatory capacity is multifaceted. They are critical in both limiting and facilitating the trafficking of various immune cell populations, including T cells and dendritic cells, out of the vasculature and into tissue. They also can be induced to stimulate immune reactivity or to be immune inhibitory. In each of these parameters (trafficking, immune stimulation and immune inhibition), their role can be physiological, whereby they have an active role in maintaining health. Alternatively, their role can be pathological, whereby they contribute to disease. In theory, endothelial cells are in an ideal location to recruit cells that can mediate immune reactivity to tumor tissue. Furthermore, they can activate the immune cells as they transmigrate across the endothelium into the tumor. However, what is seen is the absence of these protective effects of endothelial cells and, instead, the endothelial cells succumb to the defense mechanisms of the tumor, resulting in their acquisition of a tumor-protective role. To understand the immune regulatory potential of endothelial cells in protecting the host versus the tumor, it is useful to better understand the other circumstances in which endothelial cells modulate immune reactivities. Which of the multitude of immune regulatory roles that endothelial cells can take on seems to rely on the type of stimulus that they are encountering. It also depends on the extent to which they can be manipulated by potential dangers to succumb and contribute toward attack on the host. This review will explore the physiological and pathological roles of endothelial cells as they regulate immune trafficking, immune stimulation and immune inhibition in a variety of conditions and will then apply this information to their role in the tumor environment. Strategies to harness the immune regulatory potential of endothelial cells are starting to emerge in the non-tumor setting. Results from such efforts are expected to be applicable to being able to skew endothelial cells from having a tumor-protective role to a host-protective role.

Indexed as

Cell MovementAnimalsB-LymphocytesDendritic CellsEndothelial CellsHumansMiceNeoplasmsT-Lymphocytes

Identifiers

PMID22903347
PMCPMC3448862
OpenAlexW2121941407

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.